Value of the Quadrivalent HPV Vaccine  by Villa, L.L.
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rior to surgery, and disinfection of the surgical site. Last,
ut not least, surveillance of SSIs is a well-established, well
ocumented approach to lower the incidence of SSIs. Many
ospitals still do not follow this recommendation despite
ts effectiveness. Endoscopy and robotic surgeries are new
evelopments that further help to keep rates of SSIs at
he lowest possible level. However, as patients leave the
ospital at a very early stage, post-discharge surveillance
ecomes mandatory. Many studies indicate that about 50%
f the SSIs undergo undetected unless postdischarge surveil-
ance is performed.
A lot of research has been performed in the last decade:
owever, many hospital still fail to implement these new
nowledge into clinical practice.
oi:10.1016/j.ijid.2008.05.082
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invited)
8.001
ultivalent Protection Against a Severe Pediatric Disease
Rotavirus
. Christie
University of the West Indies, Kingston, Jamaica
otaviruses are the foremost cause of severe gastroenteri-
is in young children, being responsible for 600,000 deaths,
million hospitalizations, 25million clinic visits, 111million
pisodes and 56% of hospitalizations for febrile gastroenteri-
is worldwide, each year. Every child is infected by age ﬁve
ears. RotateqTM is an oral, ready-to-use, 3-dose regimen
accine, containing 5 human-bovine reassortant rotavirus
erotypes given at 2, 4, 6 months of age, that is easily inte-
rated into pre-established immunization schedules. The
roduct has been studied in over 70,000 infants from all
ve continents. RotateqTM has proven efﬁcacy of 98% against
evere gastroenteritis for G1-4 strains, was well tolerated,
ncluding with respect to intussusception in prelicensure
nd postmarketing surveillance, with no increase in fever,
rritability, or hematochezia, while it reduced health care
ontacts for rotaviruses by nearly 100%. RotateqTM has FDA-
pproval and is now in use in 70 countries, with application
ending in another 75 countries, worldwide. RotateqTM is
owwidely available in USA, Canada, Australia, eleven coun-
ries in Europe, Latin America, the Caribbean and also in
ther parts of the world. RotateqTM is now in the review pro-
ess for WHO-prequaliﬁcation. Given the universal nature of
otavirus gastroenteritis, this vaccine is an extremely impor-
ant public health priority.
oi:10.1016/j.ijid.2008.05.083
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ong Term Beneﬁts of the Quadrivalent Human Papillo-
avirus Vaccine (HPV)
. Garland
The Royal Womens Hospital, Victoria, Australia
t is now realised that 99.7% of cervical cancers are caused
y oncogenic HPV infection: and worldwide HPV types 16 and
8 consistently account for 70% to 80% of cases. Moreover
PV types 16 and 18 contribute to 50% of high-grade dys-
lasias, and 25% of low-grade dysplasias. In addition, HPV is
he most common viral infection with condylomata accumi-
ata or genital warts (90% caused by HPV 6/11) being the
ost common viral sexually transmitted disease. Genital
arts peak in the mid-20 age group, commonly recur post-
reatment, and consequently are a costly burden in sexual
ealth settings, as well as causing signiﬁcant psychosocial
orbidity to those infected.
In phase III clinical trials of the quadrivalent human papil-
omavirus vaccine (6,11,16,18), vaccine HPV type-related
IN2/3, VIN 2/3 and VaIN 2/3 were used as surrogate
ndpoints in determining efﬁcacy against cervical, vulvar
nd vaginal cancers, respectively. Randomized, placebo-
ontrolled, double-blind trials involving more than 25,000
omen aged 15 - 26 years have shown up to 100% efﬁcacy
gainst HPV 6, 11, 16 and 18 related CIN2/3, AIS (adenocar-
inoma in situ), VIN, VaIN, as well as genital warts. Through
years of follow-up, the clinical efﬁcacy was maintained
ith no breakthrough cases observed in the vaccine group.
nmid adult women aged 24 - 45, the efﬁcacy of quadrivalent
PV vaccine in the prevention of HPV6/11/16/18-related
IN or external genital lesions (EGL) was 92.4%, with efﬁcacy
gainst HPV16/18-related CIN or EGL being 87.8%. Efﬁcacy
gainst HPV6/11-related CIN or EGL was 100%.
In all studies, vaccine was generally well-tolerated,
ith a signiﬁcant but slightly higher proportion of subjects
eporting one or more injection site adverse experiences
han the placebo group.
oi:10.1016/j.ijid.2008.05.084
8.003
alue of the Quadrivalent HPV Vaccine
.L. Villa
Ludwig Institute for Cancer Research, Brazil
accines provide long-term protection by inducing immune
emory - the ability to rapidly produce high antibody lev-
ls on subsequent encounters with pathogens targeted by
he vaccine. Prophylactic administration of a quadrivalent
PV (types 6/11/16/18) L1 VLP vaccine (GARDASIL®, Merck
Co., Inc.) to 16- to 23-year-olds was 96% effective in
reventing HPV 6/11/16/18 persistent infection or related
isease through 5 years of follow-up (Villa et al., Br J Cancer,
006). Sustained efﬁcacy against disease was maintained
ith no breakthrough cases of HPV 6, 11, 16 or 18-related
nfection or disease. In the same study, at the 5 year mark,
n antigen challenge was given that demonstrated that
ARDASIL® (formulated on a proprietary aluminum adju-
ant) had induced immune memory, a hallmark of vaccines
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that induce long-lasting protection (Olsson et al., 2007). It is
not known what level of antibodies indicates an individual’s
ability to fend off HPV infection, but the available data do
suggest that HPV vaccines would provide a lengthy period of
protection, likely to usher a vaccinated individual through
the years of highest infection risk and beyond. Additional
studies are ongoing to verify these projections. Based on
demonstrated clinical efﬁcacy and favorable safety proﬁle,
this quadrivalent HPV prophylactic vaccine is being intro-
duced as a cost-effective means for reducing the morbidity
and mortality of cervical/anogenital cancers, as well as the
emotional and economic burdens of abnormal Pap tests and
genital warts. Compared to a vaccine containing VLPs of only
HPV types 16 and 18, the reduction of HPV-associated dis-
ease burden is anticipated to be signiﬁcantly higher with the
administration of the quadrivalent HPV vaccine, since HPV 6
and 11 are responsible for approximately 90% of all genital
warts and 15% of low-grade cervical neoplasias. The quadri-
valent HPV vaccine is the ﬁrst and only to show 100% efﬁcacy
against HPV 6, 11, 16 and 18-related external genital lesions
including genital warts, vulvar and vaginal cancers. More-
over, the prevention and cost-savings from HPV 6/11 related
diseases will begin relatively early in the ﬁrst years follow-
ing vaccine introduction making the quadrivalent vaccine
particularly attractive to national policy-makers.
doi:10.1016/j.ijid.2008.05.085
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Global Use of Seasonal Inﬂuenza Vaccine
D.S. Fedson
Sergy Haut, France
For several years, the Macroepidemiology of Inﬂuenza Vac-
cination Study Group (MIVSG) has documented inﬂuenza
vaccine distribution, recommendations and reimbursement
in an increasing number of countries throughout the world.
In 2003, 56 MIVSG countries used 275 million (M) doses,
94% of the 292M doses distributed worldwide. By 2005, the
MIVSG had grown to include 73 countries. These countries
used approximately 330M doses of seasonal vaccine. In most
countries, levels of vaccine use (doses distributed/1000
total population) showed relatively little change between
2002, the year before the re-emergence of H5N1 inﬂuenza,
and 2005, although large differences persisted between
individual countries. However, six countries (Belgium, El
Salvador, Japan, Latvia, Malta and Mexico) showed substan-
tial increases in vaccine use over this period, and Malta’s
increase from 124 to 657 doses/1000 was remarkable. In a
few countries, vaccine use decreased, sometimes due to
supply shortages. Some form of public reimbursement for
vaccination was provided in approximately 60% of the sur-
veyed countries, and they tended to have higher levels of
vaccine use compared with countries with no public reim-
bursement. Vaccination recommendations for risk groups
showed little change compared with earlier years, although
the age cut-off levels for vaccinating older adults decreased
in several countries. More interesting, by 2005, seven coun-
B
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ries had adopted policies for vaccinating children 6-23
onths in age. In the US, the upper age limit for children
as extended to 5 years in 2006 and to 18 years in 2008.
In 2005, nine vaccine-producing countries used 59% of
ll doses of seasonal inﬂuenza vaccine, but had only 12%
f the world’s population. Inﬂuenza vaccination is gradually
ncreasing in many countries, especially in those with rapidly
eveloping economies. This growth in seasonal vaccine use
ill lay the foundation for vaccination programs when the
ext pandemic occurs.
oi:10.1016/j.ijid.2008.05.086
9.002
he Potential Beneﬁts of Intradermal Vaccination
.J. Ward
McGill University Health Center, Montreal, Canada
he intradermal (ID) route of immunization has a fair claim
o primacy since the smallpox vaccine was administered via
he skin for almost 100 years before the next human vaccine
as introduced. Despite this early success and long-standing
mmunological interest in this route, the large majority of
urrent vaccines are administered either via the intramus-
ular or subcutaneous routes. The accessibility of the skin
s obvious and the potential immunological advantages of ID
mmunization have been known for some time. Animal mod-
ls of ID vaccination have generally yielded excellent results
ith a range of microbial antigens and several ID vaccines
ave been successfully introduced for human infections such
s rabies and hepatitis B. The skin is the largest immune
organ’ of the human body and, unlike subcutaneous and
uscle tissues, the skin has evolved speciﬁcally to limit the
enetration of chemical andmicroorganisms. As a result, the
kin is better prepared than most tissues to actively screen
or invasive microbes and to mount appropriate innate and
daptive immune responses. The immunologic characteris-
ics and capabilities of the skin have been the subject of
onsiderable research for many years due to this unique
front line’ position. Until recently however, full exploita-
ion of the potential of the ID route for vaccination has been
ampered by the lack of simple, reliable and safe injection
ystems. Recent advances in delivery system technologies
ave sparked renewed interest in the ID route for both
stablished and new vaccines. This presentation will provide
n overview of the potential immunological and practical
dvantages of ID vaccination as well as a brief review of
istorical and recent ID vaccination techniques.
oi:10.1016/j.ijid.2008.05.087
9.003
linical Development of a Seasonal Inﬂuenza Vaccine by
ntradermal Micro-injection
. SavilleSanoﬁ Pasteur, Marcy l’Etoile, France
ackground: Annual trivalent inactivated inﬂuenza vaccines
TIV) provide protection for hundreds of millions of individu-
ls worldwide. Yet there is need to improve vaccine efﬁcacy
